UK markets open in 6 hours 5 minutes

Sorrento Therapeutics, Inc. (0L85.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
1.0115-0.0435 (-4.12%)
At close: 05:30PM GMT

Sorrento Therapeutics, Inc.

4955 Directors Place
San Diego, CA 92121
United States
858 203 4100

Full-time employees799

Key executives

NameTitlePayExercisedYear born
Dr. Henry H. Ji Ph.D.Chairman, Pres & CEO1.69M34.1k1964
Ms. Elizabeth Adkins Czerepak M.B.A.Exec. VP, CFO & Chief Bus. Officer8.12kN/A1956
Mr. Brian CooleySr. VP of Corp. Communications & Lymphatic Drug Devel. BUN/AN/AN/A
Dr. Michael A. Royal J.D., M.D., MBASVP & Chief Medical OfficerN/AN/A1954
Dr. Alexis Nahama D.V.M.Sr. VP of Neurotherapeutics BUN/AN/AN/A
Dr. Mark R. BrunswickSr. VP of Regulatory AffairsN/AN/AN/A
Dr. Shawn Sahebi Ph.D.Sr. VP of Commercial OperationsN/AN/AN/A
Dr. Robert D. Allen Ph.D.Sr. VP of R&DN/AN/AN/A
Dr. Xiao Xu M.D.Pres of ACEAN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Corporate governance

Sorrento Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 6; Board: 10; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.